Zanamivir
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00558 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 56 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | pyelonephritis | KG + DL |
| 2 | disorder of tyrosine metabolism | KG + DL |
| 3 | teratogenic Pierre Robin syndrome | KG + DL |
| 4 | disorder of phenylalanine metabolism | KG + DL |
| 5 | tetrahydrobiopterin-responsive hyperphenylalaninemia/phenylketonuria | KG + DL |
| 6 | susceptibility to HIV infection | KG + DL |
| 7 | dengue virus, susceptibility to | KG + DL |
| 8 | legionnaire disease, susceptibility to | KG + DL |
| 9 | aspergillosis, susceptibility to | KG + DL |
| 10 | Schistosoma mansoni infection, susceptibility | KG + DL |
| 11 | cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency | KG + DL |
| 12 | staphylococcus aureus infection | KG + DL |
| 13 | pyogenic bacterial infections due to MyD88 deficiency | KG + DL |
| 14 | acute hemorrhagic encephalitis | KG + DL |
| 15 | acute necrotizing encephalitis | KG + DL |
| 16 | HHV-6 encephalitis | KG + DL |
| 17 | Hendra virus infection | KG + DL |
| 18 | equine encephalitis | KG + DL |
| 19 | Kaposi sarcoma, susceptibility to | KG + DL |
| 20 | hyperamylasemia | KG + DL |
| 21 | polyclonal hyperviscosity syndrome | KG + DL |
| 22 | Nipah virus disease | KG + DL |
| 23 | congenital analbuminemia | KG + DL |
| 24 | streptococcal pneumonia | KG + DL |
| 25 | blood group incompatibility | KG + DL |
| 26 | premalignant hematological system disease | KG + DL |
| 27 | monoclonal gammopathy | KG + DL |
| 28 | herpes simplex encephalitis | KG + DL |
| 29 | hematological disease associated with an acquired peripheral neuropathy | KG + DL |
| 30 | congenital hematological disorder | KG + DL |
| 31 | pneumonia | KG + DL |
| 32 | neonatal epileptic encephalopathy due to glutaminase deficiency | KG + DL |
| 33 | genetic otorhinolaryngological malformation | KG + DL |
| 34 | semicircular canal dehiscence syndrome | KG + DL |
| 35 | idiopathic bilateral vestibulopathy | KG + DL |
| 36 | inherited susceptibility to mycobacterial diseases | KG + DL |
| 37 | pleural adenomatoid tumor | KG + DL |
| 38 | inborn disorder of phenylalanin or tyrosine metabolism | KG + DL |
| 39 | pleural biphasic mesothelioma | KG + DL |
| 40 | septicemic plague | KG + DL |
| 41 | hematopoietic and lymphoid system neoplasm | KG + DL |
| 42 | propylthiouracil embryofetopathy | KG + DL |
| 43 | lymphohistiocytoid mesothelioma | KG + DL |
| 44 | juvenile nasopharyngeal angiofibroma (disease) | KG + DL |
| 45 | familial nasal acilia | KG + DL |
| 46 | tetrahydrobiopterin metabolic process disease | KG + DL |
| 47 | pleural epithelioid mesothelioma | KG + DL |
| 48 | silent sinus syndrome | KG + DL |
| 49 | pericardium cancer | KG + DL |
| 50 | pleural sarcomatoid mesothelioma | KG + DL |
(Showing top 50 of 56 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.